EY with Polifarma on the acquisition of Hennig Arzneimittel

Polifarma, an Italian pharmaceutical company headquartered in Rome, active in the marketing and distribution of pharmaceuticals, medical devices and food supplements in various therapeutic areas, has acquired 100% of Hennig Arzneimittel, a German pharmaceutical company with over 120 years of active experience in the development, manufacturing and marketing of innovative drugs in the treatment of balance disorders and vertigo, for pain and for cardiovascular, metabolic and neurological conditions. Hennig also offers contract manufacturing services, including development and technology transfer for oral solid dosage forms.

EY Law Germany, together with EY STS Italy, acted as legal advisors to Polifarma, dealing with the corporate aspects of German and Italian law with a team composed of partners Matthias Winter (PICTURED), Luca Iannaccone, Francesco Aratari, director Ines Fritz, and senior manager Sara Reverso. EY SLT also handled the aspects relating to the negotiation of the financing agreement with Banca Patrimoni Sella, the financier of the operation, with a team coordinated by partner Carlo Lichino and composed of manager Francesco Paolo Sasso, associate Camilla Capaldo and trainee Anxhela Brahushaj.

In the operation, Deloitte Financial Advisory assisted Polifarma as financial advisor. Deloitte also conducted due diligence activities.